UNSPSC 51422114: Diflucortolone valerate

This classification denotes a therapeutic glucocorticoid with the molecular formula C27H36F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1A63Z067C8, chemically known as 6-alpha,9-difluoro-11-beta-hydroxy-21-valeryloxy-16-alpha-methyl-1,4-pregnadiene-3,20-dione but more generally known as diflucortolone valerate, which bears US NIH Compound Identifier 91670. European Medicines Agency schedules Diflucortolone valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01694MIG.

Most nations, for tariff and trade purposes, schedule diflucortolone valerate under HS 29372200 and SITC 54153. As of Q4 2014, DIFLUCORTOLONE VALERATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC(=O)OCC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C.

UNSPSC 51422114 Diflucortolone valerate is a Commodity code for a topical corticosteroid pharmaceutical product. However, the recent state and local solicitations tagged under this code do not align with the product scope — Seminole County, Florida solicited naloxone and drug deactivation systems, while the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer pharmacy programs. Neither opportunity involves diflucortolone valerate procurement. The code shows little relevant recent activity aligned with its stated pharmaceutical category.

The mismatch between the code's nominal scope and the posted opportunities suggests either tagging error or that diflucortolone valerate procurement does not currently generate state and local contract notices in publicly available databases. Business development professionals evaluating this code should verify whether tagged opportunities reflect actual buying patterns or whether purchasing activity for this steroid product occurs through other channels — such as cooperative purchasing frameworks, blanket orders, or bundled pharmaceutical agreements — that may not be surfaced as discrete solicitations.